BR0012865A - Uma forma amorfa aperfeiçoada da proxetil cefpodoxima - Google Patents
Uma forma amorfa aperfeiçoada da proxetil cefpodoximaInfo
- Publication number
- BR0012865A BR0012865A BR0012865-1A BR0012865A BR0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A
- Authority
- BR
- Brazil
- Prior art keywords
- amorphous form
- improved
- cefpodoxime proxetil
- improved amorphous
- proxetyl
- Prior art date
Links
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 title 1
- -1 2-amino- 4-thiazolyl Chemical group 0.000 abstract 4
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 abstract 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229960005090 cefpodoxime Drugs 0.000 abstract 1
- 125000004494 ethyl ester group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1036DE1999 IN191496B (member.php) | 1999-07-30 | 1999-07-30 | |
| PCT/IB2000/001024 WO2001009143A1 (en) | 1999-07-30 | 2000-07-24 | An improved amorphous form of cefpodoxime proxetil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0012865A true BR0012865A (pt) | 2002-07-09 |
Family
ID=11092065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0012865-1A BR0012865A (pt) | 1999-07-30 | 2000-07-24 | Uma forma amorfa aperfeiçoada da proxetil cefpodoxima |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6602999B1 (member.php) |
| EP (1) | EP1204667A4 (member.php) |
| JP (1) | JP2003506329A (member.php) |
| CN (1) | CN1371381A (member.php) |
| AU (1) | AU5839100A (member.php) |
| BR (1) | BR0012865A (member.php) |
| IN (1) | IN191496B (member.php) |
| WO (1) | WO2001009143A1 (member.php) |
| ZA (1) | ZA200200692B (member.php) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT408226B (de) * | 1999-05-05 | 2001-09-25 | Biochemie Gmbh | Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2 |
| EP1373276A4 (en) | 2001-02-27 | 2005-03-02 | Ranbaxy Lab Ltd | PROCESS FOR THE PRODUCTION OF CEFPODOXIM PROXETIL |
| CA2582087A1 (en) * | 2004-10-18 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| AU2006344711A1 (en) * | 2005-05-16 | 2008-01-24 | Alkermes Pharma Ireland Limited | Nanoparticulate and controlled release compositions comprising a cephalosporin |
| KR100840132B1 (ko) * | 2007-04-17 | 2008-06-23 | 재단법인서울대학교산학협력재단 | 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조 |
| EP4450130A3 (en) * | 2012-09-11 | 2025-01-08 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| AU2013316754A1 (en) * | 2012-09-11 | 2015-04-30 | Dr. Reddy's Laboratories Limited | Enzalutamide polymorphic forms and its preparation |
| IL302877A (en) | 2015-03-06 | 2023-07-01 | Atea Pharmaceuticals Inc | Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus |
| WO2017046756A1 (en) * | 2015-09-18 | 2017-03-23 | Lupin Limited | Proxetil and axetil esters of cefixime |
| US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
| US11773113B2 (en) * | 2016-05-09 | 2023-10-03 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
| CN114409665A (zh) * | 2016-06-16 | 2022-04-29 | 泽农医药公司 | 螺-吲哚酮化合物的固态形式 |
| WO2018046337A1 (en) * | 2016-09-06 | 2018-03-15 | Indena S.P.A. | Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same |
| KR102456417B1 (ko) | 2016-09-07 | 2022-10-19 | 아테아 파마슈티컬즈, 인크. | Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드 |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| RS66554B1 (sr) * | 2017-02-01 | 2025-03-31 | Atea Pharmaceuticals Inc | Nukleotid hemi-sulfat so za lečenje virusa hepatitisa c |
| CN110446705B (zh) * | 2017-03-30 | 2023-04-14 | 默克专利股份公司 | (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式 |
| TWI808108B (zh) * | 2017-11-22 | 2023-07-11 | 美商阿吉歐斯製藥公司 | N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型 |
| EP3773591A4 (en) * | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL KINASE INHIBITORS AND THEIR USE |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| CN110251467A (zh) * | 2019-06-26 | 2019-09-20 | 北京济美堂医药研究有限公司 | 一种无定形态头孢妥仑匹酯组合物的制备方法 |
| CN110437259B (zh) * | 2019-08-14 | 2021-12-07 | 中国药科大学 | 头孢泊肟酯柚皮素共无定形物及其制备方法 |
| US20220380348A1 (en) * | 2019-10-04 | 2022-12-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl inhibitor formulations |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| CA3174073A1 (en) | 2021-06-17 | 2022-12-17 | Atea Pharmaceuticals, Inc. | Advantageous anti-hcv combination therapy |
| KR20250008762A (ko) | 2022-05-23 | 2025-01-15 | 국립대학법인 나고야공업대학 | 습식 방사법을 사용하여 무기 필러 입자를 함유하는 생분해성 섬유 재료를 연속적으로 제조하는 방법, 및 그 방법으로 제조된 코튼 형상의 뼈 재생 재료 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4223153A (en) | 1979-02-09 | 1980-09-16 | Eli Lilly And Company | Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea |
| IT1165253B (it) | 1979-07-12 | 1987-04-22 | Blasinachim Spa | Procedimento di fabbricazione di acido chenodesossicolico cristallino puro |
| US4486425A (en) | 1980-09-30 | 1984-12-04 | Sankyo Company Limited | 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates |
| YU44680B (en) * | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
| IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| DE59209994D1 (de) * | 1991-09-07 | 2004-04-29 | Aventis Pharma Gmbh | Diastereomer des 3-Cephem-4-carbonsäure-1-(-isopropoxycarbonyloxy)ethylesters und Verfahren zu dessen Herstellung |
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| AT413383B (de) * | 1998-01-09 | 2006-02-15 | Sandoz Ag | Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil |
| KR100342943B1 (ko) | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
-
1999
- 1999-07-30 IN IN1036DE1999 patent/IN191496B/en unknown
-
2000
- 2000-07-24 US US10/048,354 patent/US6602999B1/en not_active Expired - Fee Related
- 2000-07-24 AU AU58391/00A patent/AU5839100A/en not_active Abandoned
- 2000-07-24 CN CN00812246A patent/CN1371381A/zh active Pending
- 2000-07-24 JP JP2001513950A patent/JP2003506329A/ja active Pending
- 2000-07-24 WO PCT/IB2000/001024 patent/WO2001009143A1/en not_active Ceased
- 2000-07-24 BR BR0012865-1A patent/BR0012865A/pt not_active Application Discontinuation
- 2000-07-24 EP EP00944159A patent/EP1204667A4/en not_active Withdrawn
-
2002
- 2002-01-25 ZA ZA200200692A patent/ZA200200692B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6602999B1 (en) | 2003-08-05 |
| IN191496B (member.php) | 2003-12-06 |
| JP2003506329A (ja) | 2003-02-18 |
| ZA200200692B (en) | 2003-05-28 |
| WO2001009143A1 (en) | 2001-02-08 |
| CN1371381A (zh) | 2002-09-25 |
| AU5839100A (en) | 2001-02-19 |
| EP1204667A1 (en) | 2002-05-15 |
| EP1204667A4 (en) | 2002-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0012865A (pt) | Uma forma amorfa aperfeiçoada da proxetil cefpodoxima | |
| Deshpande et al. | Degradation of β-lactam antibiotics | |
| CA1037949A (en) | Cephalosporin derivatives | |
| IE831527L (en) | Preparation of azetidinooxazole derivatives | |
| WO2001073103A3 (en) | Preparation of epothilone intermediates | |
| UY23757A1 (es) | Procedimiento para la preparación de derivados de cefalosporina.- | |
| BR0112598A (pt) | Processo para a preparação de (r,s)-axetil cefuroxima cristalina de alta pureza | |
| CA2103696A1 (en) | A method for the acylation of the 7-amino group of the cephalosporanic ring | |
| KR100667143B1 (ko) | 가용성 측쇄 에스테르와 효소 아실라제를 사용하는 β-락탐 항균 물질의 합성법 | |
| US6919449B2 (en) | Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds | |
| CA2292618C (en) | Improved precipitation process of 7-aminocephalosporanic acid (7-aca) | |
| KR910018388A (ko) | 세팔로스포린 제조방방방법 | |
| GB1497039A (en) | Penicillins and cephalosporins | |
| CN100368554C (zh) | 酶催化“一锅法”制备β-内酰胺抗生素的方法 | |
| BR9301627A (pt) | Processo para preparar cefalosporinas | |
| ATE244248T1 (de) | Herstellung von amino cephalosporansäurederivaten | |
| AU8404701A (en) | Butinol I esterase | |
| DE60233307D1 (de) | Verfahren zur herstellung optisch aktiver propoxyanilinderivate | |
| DE60205635D1 (de) | Einfaches enzymatisches Verfahren zur Herstellung von Cefazolin | |
| FI58132B (fi) | Foerfarande foer framstaellning av 3-metyl- 3-cefem-4-karboxylsyrafoereningar | |
| EP0742219B1 (en) | Preparation and use of 7-((2-carbo-alkoxy-1-methylethenyl) amino)-3-hydroxymethyl-3-cephem-4-carboxylic acids | |
| WO2004081220A3 (en) | A process for enzymatically resolving an enantiomeric mixture of alpha-hydroxy acids | |
| AU4757000A (en) | Method of producing methoxyimino acetic amide | |
| GB1261780A (en) | Orally active sulfur-containing cephalosporin antibiotics | |
| KR890000497A (ko) | 아실 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |